Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 PatientsGian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
Haematologica|October 6, 2022
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysisSilvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseRoberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.
Haematologica|November 20, 2023
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agentsRoberto Mina, Maria Teresa Petrucci, Francesca Bonello, et al.
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSPaula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
The Lancet. Haematology|January 5, 2025
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Pageof 8